# Caribou Biosciences

Source: https://onco.cc/companies/caribou/  
OnCo record `caribou` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CRISPR-edited allogeneic CAR-T company whose vispa-cel (CB-010) matched autologous CAR-T efficacy in lymphoma in 2025 data.

## Summary

Vispacabtagene regedleucel (CD19, chRDNA-edited) holds RMAT, Orphan, and Fast Track designations for B-NHL; ANTLER phase 1 data (November 2025) showed efficacy and durability on par with autologous products and outpatient-compatible safety; enrolling ~20 more second-line LBCL patients to confirm an HLA-matching strategy; IND cleared in lupus.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Berkeley, CA
- Type: cell-therapy
- Website: https://www.cariboubio.com
- Ticker: CRBU

## Sources

- ANTLER data: https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-positive-data-antler-phase-1-trial

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [Allogeneic cell banks: one donor, hundreds of doses](https://onco.cc/technologies/allogeneic-cell-banks/), [Allogeneic donor and iPSC master cell banks](https://onco.cc/technologies/allogeneic-cell-banking/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [CRISPR functional genomics](https://onco.cc/technologies/crispr-screens/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/)

---
JSON: https://onco.cc/api/v1/entities/caribou.json